Reata Pharmaceuticals Inc (RETA)


Stock Price Forecast

Sept. 26, 2023


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Reata Pharmaceuticals Inc chart...

About the Company

reata pharmaceuticals, inc. (nasdaq:reta) is a clinical-stage biopharmaceutical company that develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways involved in the regulation of cellular metabolism and inflammation. reata’s two most advanced clinical candidates, bardoxolone methyl and omaveloxolone, target the important transcription factor nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation.

CEO

J. Warren Huff

Exchange

NASDAQ

Website

https://reatapharma.com/

$32M

Total Revenue

372

Employees

$1B

Market Capitalization

-31.48

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $RETA News

Reata Pharmaceuticals Stock Plummets More Than 20%: Here's Why

10mon ago, source: Hosted on MSN

Reata Pharmaceuticals Inc (NASDAQ: RETA) and its partner Kyowa Kirin Co Ltd have decided to discontinue bardoxolone chronic kidney disease programs. In May 2023, Kyowa Kirin announced data from ...

Reata Pharmaceuticals Inc Class A

4y ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Levi & Korsinsky, LLP Notifies Shareholders of Reata Pharmaceuticals, Inc. (RETA) an Upcoming Claims Deadline in a Class Action Settlement

21d ago, source: Business Insider

NEW YORK, NY / ACCESSWIRE / March 7, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against Reata Pharmaceuticals, Inc. (NASDAQ ...

Reata Pharmaceuticals

1mon ago, source: D Magazine

Projects include: 3401 & 3501 Olympus Blvd, HQ53, Reata Pharmaceuticals, The Offices Two at Frisco Station, and Victory Commons One. North Texas corporate lawyers share insights about moving ...

AbbVie Inc.'s Net Worth

1mon ago, source: Benzinga.com

AbbVie Inc. has an estimated net worth of $10.1 Million. This is based on reported shares in REATA PHARMACEUTICALS INC. Attention insiders: Dive deeper into market movements and stay ahead of the ...

Quince Therapeutics Appoints Former Reata Pharmaceuticals Chief R&D Officer Dr. Rajiv Patni to its Board of Directors

1mon ago, source: Morningstar

Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology ... Most recently, he served as Chief Research and Development Officer at Reata Pharmaceuticals, a commercial-stage company ...

Why Is Biogen Inc. (BIIB) Up 2.6% Since Last Earnings Report?

14d ago, source: Zacks.com on MSN

It has been about a month since the last earnings report for Biogen Inc. (BIIB). Shares have added about 2. ... which was added with the September 2023 acquisition of Reata Pharmaceuticals, generated ...

CNSP CNS Pharmaceuticals, Inc.

16d ago, source: Seeking Alpha

It has license agreements with Houston Pharmaceuticals, Inc., Reata Pharmaceuticals, Inc., Pomeranian Medical University, and The University of Texas M.D. Anderson Cancer Center; and a development ...

Levi & Korsinsky, LLP Notifies Shareholders of Reata Pharmaceuticals, Inc. (RETA) an Upcoming Claims Deadline in a Class Action Settlement

16d ago, source: Business Insider

NEW YORK, NY / ACCESSWIRE / March 12, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against Reata Pharmaceuticals, Inc. (NASDAQ: ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...